C0038250||Stem cell
C0349782||ischemic cardiomyopathy
C0010055||coronary artery bypass grafting
C0038136||Standardization
C2911685||methods
C0220825||evaluate
C3178990||pharmacovigilance
C0018017||objective
C0037585||registry programme
C0349782||ischemic cardiomyopathy
C0027061||intramyocardial
C1511246||CD133+ bone marrow mononuclear stem cell
C0087111||treatment
C0010055||coronary artery bypass grafting
C0010055||coronary artery bypass grafting
C0010055||coronary artery bypass grafting
C0243095||adverse cerebral
C1556247||cardiac events
C0220825||evaluated
C1522577||follow-up
C1257890||population
C0919876||responders
C0919875||non-responders
C0936012||analysis
C0184785||good response
C1511246||CD133+ bone marrow mononuclear stem cell
C0087111||treatment
C1504389||stem cells transplantation
C0243095||no significant
C0243095||adverse cardiovascular
C0243095||cerebral events
C0038250||stem cell
C1522577||follow-up
C0428772||left ventricle ejection fraction
C0428772||left ventricle ejection fraction
C0038250||stem cell
C0010055||coronary artery bypass grafting
C0428772||left ventricle ejection fraction
C0428772||left ventricle ejection fraction
C0919652||left ventricle end diastolic diameter
C0007634||CD133+ cell
C0302189||therapy
C0679646||Participants
C0018801||overt heart failure
C0010055||coronary artery bypass grafting
C0027061||intramyocardial
C1533685||injection
C1511246||CD133+ bone marrow mononuclear cell
C0428772||left ventricle ejection fraction
C0038250||stem cell
C0010055||coronary artery bypass grafting
C0428772||left ventricle ejection fraction
C0919652||LVED